2023 World Conference on Lung Cancer (Posters)-EP12.01. Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort

EP12.01. Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort - PDF(Slides)

Back to course

Pdf Summary

A study was conducted in Canada to identify the clinical characteristics associated with long-term survival in patients with advanced non-small cell lung cancer (NSCLC) who had a specific mutation called EGFR. These patients were treated with tyrosine kinase inhibitors (TKIs), a type of targeted therapy. The study aimed to provide insights into the factors that influence the outcome of EGFR-positive NSCLC patients in a more ethnically diverse population.<br /><br />The study confirmed previously known prognosticators, such as patients of Asian ancestry having improved outcomes, while males and those with the L858R mutation had poorer outcomes. The results also showed that the presence of Asian ancestry and being treated at a specific center called Princess Margaret Hospital (PM) were independently associated with longer survival times. The study found that patients with long-term survival (LTS) had a median survival of 56 months from the initiation of TKI treatment, whereas patients with average term survival (ATS) had a median survival of 17.5 months.<br /><br />The study had some limitations, including its retrospective nature, which means that it relied on existing data and could not account for all potential confounding factors. It was also observed that patients from PM had a significantly higher proportion of Asian ancestry compared to another center called Glans-Look Research Program (GLR), which may explain the difference in overall survival between the two centers.<br /><br />In conclusion, this multicenter Canadian study confirmed the influence of certain clinical characteristics on the long-term survival of patients with EGFR-positive NSCLC treated with TKIs. The results highlighted the importance of considering factors such as ethnicity and mutation type when determining treatment strategies for these patients. Further research is needed to understand the biological reasons behind these ethnic disparities and the impact of socio-economic factors on patient outcomes.

Asset Subtitle

Heather Halperin

Meta Tag

Speaker Heather Halperin

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

Canada

clinical characteristics

long-term survival

NSCLC

EGFR mutation

tyrosine kinase inhibitors

ethnic diversity

Asian ancestry

L858R mutation

multicenter study